BioNTech (NASDAQ:BNTX) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen cut shares of BioNTech (NASDAQ:BNTX - Free Report) from a hold rating to a sell rating in a research report released on Friday.

BNTX has been the subject of a number of other research reports. BMO Capital Markets raised their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Morgan Stanley dropped their price objective on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Canaccord Genuity Group reissued a "buy" rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and set a $134.00 price target on shares of BioNTech in a research report on Thursday, May 22nd. Finally, The Goldman Sachs Group started coverage on BioNTech in a research note on Thursday. They set a "neutral" rating and a $110.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $140.14.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $17.29 during midday trading on Friday, reaching $113.10. The company's stock had a trading volume of 5,259,451 shares, compared to its average volume of 927,317. The stock has a market capitalization of $27.19 billion, a P/E ratio of -53.86 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a 50 day moving average price of $97.44 and a 200-day moving average price of $108.12. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The business's revenue was down 19.5% on a year-over-year basis. As a group, equities analysts predict that BioNTech will post -3.88 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Banque Cantonale Vaudoise bought a new stake in shares of BioNTech during the 1st quarter valued at about $36,000. Jones Financial Companies Lllp raised its stake in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Banque Transatlantique SA bought a new stake in BioNTech during the first quarter valued at approximately $80,000. Quintet Private Bank Europe S.A. grew its stake in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after buying an additional 700 shares in the last quarter. Finally, Allianz SE bought a new position in shares of BioNTech in the 4th quarter worth $90,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.